Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus Gemcitabine in Advanced Sarcoma
NCT04595994Phase 1Recruiting
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Sep 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selinexor in soft tissue sarcoma (STS) and osteosarcoma (OS) (2 arms), sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Sep 2020; status: recruiting.
02
Drugs
selinexor
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04595994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595994.